An Antimicrobial Blue Light Prototype Device Controls Infected Wounds in a Preclinical Porcine Model
By
Laisa Bonafim Negri
William Farinelli
Sandeep Korupolu
Ying Wang
Yara Mannaa
Hang Lee
Jie Hui
Pu-Ting Dong
Andrea Slate
Joshua Tam
R Rox Anderson
Seok-Hyun Andy Yun
Jeffrey A Gelfand
November 13, 2024
Clinical Scorecard: A Prototype Antimicrobial Blue Light Device Effectively Manages Infected Wounds in a Preclinical Swine Model
At a Glance
Category Detail
Condition Cutaneous wound infections with high-bioburden MRSA biofilm Key Mechanisms Antimicrobial blue light (405 nm) induces intracellular reactive oxygen species via endogenous bacterial chromophores, leading to bacterial cell death Target Population Patients with infected skin wounds, especially those with antibiotic-resistant biofilm infections Care Setting Wound care settings including clinical and potentially outpatient environments
Key Highlights
ABL device reduced MRSA bacterial burden by >99.99% after 2 daily treatments in a porcine partial-thickness wound model ABL acts via photochemical generation of reactive oxygen species, effective against antibiotic-resistant bacteria including biofilms Device integrates cooling to maintain safe skin temperature (~35°C) and uses FDA-approved PDMS dressing material Guideline-Based Recommendations
Diagnosis
Identify cutaneous wound infections with high bacterial bioburden, particularly MRSA Recognize biofilm presence as a contributor to antibiotic resistance and chronicity Management
Consider adjunctive use of antimicrobial blue light (405 nm) to reduce bacterial load in infected wounds Use ABL in combination with standard antibiotic therapy to potentially reduce antibiotic dose and duration Maintain device cooling to ensure patient safety and prevent thermal injury Monitoring & Follow-up
Monitor bacterial burden reduction through clinical assessment and microbiological quantification Observe skin temperature during ABL treatment to maintain ~35°C ± 1°C Assess wound healing progress and signs of infection resolution Risks
Potential thermal effects mitigated by integrated cooling circuit No current FDA or EU-approved ABL devices for significant cutaneous wound infections; use investigationally Unknown long-term effects and efficacy in humans require further clinical trials Patient & Prescribing Data
Patients with partial-thickness skin wounds infected with MRSA or other antibiotic-resistant bacteria
ABL treatment significantly reduces bacterial load rapidly, potentially decreasing antibiotic use and resistance development
Clinical Best Practices
Use ABL as an adjunct, not a replacement, to antibiotic therapy in infected wounds Employ devices with integrated cooling to maintain safe skin temperatures during treatment Select patients with biofilm-associated infections for potential ABL benefit Ensure device flexibility and conformity to wound contours for uniform illumination Continue antibiotic stewardship efforts alongside ABL integration References
